GSK Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
16
Price Target
£16.10
Consensus
Neutral
Downside
-98.88%
Analysts
16
Stock Rating
16
Downside
-98.88%
Analysts
16
Price Target
£16.10

GSK Stock Forecast and Price Target

The average price target of £16.10 for GSK's stock set by sixteen distinguished analysts in recent weeks would represent a potential downside of approximately -98.88% from the last closing price in February, 2023 if reached by the end of the year. This potential increase is based on a high estimate of £25.70 and a low estimate of £11.10. If you are not interested in GSK stock, you may be interested in its competitors.

£16.10

-98.88% Downside

Hold
Hold

GSK Fair Value Forecast for 2023 - 2025 - 2030

GSK's Price has decreased In the last two years, from £15.83 to £14.50 – a 8.39% drop. In the next year, analysts believe that Fair Value will reach £15.04 – an increase of 3.71%. For the next nine years, the forecast is for Fair Value to grow by 3.58%.

2022 Fair Value Forecast
£15.04
2023 Fair Value Forecast
£15.31
2024 Fair Value Forecast
£15.14
2025 Fair Value Forecast
£14.93
2026 Fair Value Forecast
£14.97
2027 Fair Value Forecast
£15.08
2028 Fair Value Forecast
£15.10
2029 Fair Value Forecast
£15.04
2030 Fair Value Forecast
£15.02
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 10
$145.20 Buy/Sell $162.12 13.64%
AZN Stock Forecast AstraZeneca PLC Outperform 8
£10.58k Buy/Sell £153.20 -98.53%
ABT Stock Forecast Abbott Laboratories Outperform 10
$111.79 Buy/Sell $120.97 11.82%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$74.45 Buy/Sell $80.99 11.48%
AMGN Stock Forecast Amgen Inc Hold 7
$245.17 Buy/Sell $268.00 13.39%

GSK Revenue Forecast for 2023 - 2025 - 2030

In the last two years, GSK's Revenue has grown, rising from £33.75B to £34.11B – a growth of 1.07%. In the following year, 0 experts forecast GSK's Revenue will decrease by 0.36%, to £33.99B. In 2030, professionals predict that GSK's Revenue will decrease by 0.34%, to £34.00B.

2022 Rev Forecast
£33.99B
2023 Rev Forecast
£33.91B
2024 Rev Forecast
£33.97B
2025 Rev Forecast
£34.02B
2026 Rev Forecast
£34.01B
2027 Rev Forecast
£33.98B
2028 Rev Forecast
£33.98B
2029 Rev Forecast
£33.99B
2030 Rev Forecast
£34.00B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$84.50 Buy/Sell $87.30 4.14%
CSL Stock Forecast CSL Outperform 8
$313.81 Buy/Sell $218.60 -27.96%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$245.84 Buy/Sell $268.00 11.86%

GSK Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, GSK's Dividend per Share has seen a drop from £1.00 to £1.00 – a 0.00% decrease. According to 0 major analysts, GSK's Dividend per Share will fall by 0.00% in the next year, reaching £1.00. Professionals believe that By 2030, GSK's Dividend per Share will fall to £1.00– a 0.00% decrease from its current value.

2022 DPS Forecast
£1.00
2023 DPS Forecast
£1.00
2024 DPS Forecast
£1.00
2025 DPS Forecast
£1.00
2026 DPS Forecast
£1.00
2027 DPS Forecast
£1.00
2028 DPS Forecast
£1.00
2029 DPS Forecast
£1.00
2030 DPS Forecast
£1.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MMM Stock Forecast 3M Hold 16
$117.49 Buy/Sell $147.79 1.71%
CL Stock Forecast Colgate-Palmolive Co Outperform 18
$74.29 Buy/Sell $81.35 10.38%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k Buy/Sell ¥0.00 35.30%

GSK Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from £6.76B to £6.78B. For the next year, analysts predict that Free Cash Flow will reach £6.91B – an increase of 1.94%. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%.

2022 FCF Forecast
£6.91B
2023 FCF Forecast
£6.87B
2024 FCF Forecast
£6.97B
2025 FCF Forecast
£6.91B
2026 FCF Forecast
£6.91B
2027 FCF Forecast
£6.90B
2028 FCF Forecast
£6.92B
2029 FCF Forecast
£6.92B
2030 FCF Forecast
£6.91B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
56.68€ Buy/Sell 74.54€ 33.20%
ADM Stock Forecast Archer-Daniels-Midland Outperform 4
$82.28 Buy/Sell $99.07 20.32%
CTVA Stock Forecast Corteva Inc Outperform 12
$61.50 Buy/Sell $73.12 18.70%

GSK Net Income Forecast for 2023 - 2025 - 2030

In the last two years, GSK's Net Income has gone down from £4.65B to £4.39B – a 5.60% drop. In the next year, analysts believe that Net Income will reach £5.01B – an increase of 14.34%. For the next nine years, the forecast is for Net Income to grow by 15.20%.

2022 NI Forecast
£5.01B
2023 NI Forecast
£5.00B
2024 NI Forecast
£5.32B
2025 NI Forecast
£4.99B
2026 NI Forecast
£5.01B
2027 NI Forecast
£5.01B
2028 NI Forecast
£5.11B
2029 NI Forecast
£5.07B
2030 NI Forecast
£5.05B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
A Stock Forecast Agilent Technologies Outperform 17
$154.55 Buy/Sell $162.50 7.73%
ABEV3 Stock Forecast Ambev Outperform 18
R$12.98 Buy/Sell R$17.02 32.90%
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.31k Buy/Sell ¥0.00 36.03%

GSK EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, GSK's EBITDA has decreased from £10.32B to £9.91B – a 4.03% drop. In the next year, analysts predict that EBITDA will jump to £10.18B – up 2.80% from the current level. Looking ahead to nine years, experts forecast that EBITDA will grow by 2.75%.

2022 EBITDA Forecast
£10.18B
2023 EBITDA Forecast
£10.23B
2024 EBITDA Forecast
£10.27B
2025 EBITDA Forecast
£10.14B
2026 EBITDA Forecast
£10.16B
2027 EBITDA Forecast
£10.18B
2028 EBITDA Forecast
£10.21B
2029 EBITDA Forecast
£10.19B
2030 EBITDA Forecast
£10.18B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALC Stock Forecast Alcon Outperform 15
CHF66.18 Buy/Sell CHF0.00 30.51%
BN Stock Forecast Danone Hold 18
49.65€ Buy/Sell 55.47€ 11.78%
HEN3 Stock Forecast Henkel AG & Co. KGaA Hold 16
65.62€ Buy/Sell 66.02€ 1.34%

GSK EBIT Forecast for 2023 - 2025 - 2030

In the last two years, GSK's EBIT has decreased by 2.87%, going from £8.20B to £7.97B. Analysts predict that GSK's EBIT will increase in the upcoming year, reaching £8.21B. This would represent an increase of 3.00%. Over the next nine years, experts predict that GSK's EBIT will grow at a rate of 2.99%.

2022 EBIT Forecast
£8.21B
2023 EBIT Forecast
£8.21B
2024 EBIT Forecast
£8.29B
2025 EBIT Forecast
£8.18B
2026 EBIT Forecast
£8.19B
2027 EBIT Forecast
£8.20B
2028 EBIT Forecast
£8.23B
2029 EBIT Forecast
£8.21B
2030 EBIT Forecast
£8.20B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.92k Buy/Sell ¥0.00 24.74%
BEI Stock Forecast Beiersdorf Outperform 17
112.45€ Buy/Sell 110.36€ 2.27%
COLO B Stock Forecast Coloplast A/S Hold 18
kr848.20 Buy/Sell kr1.05k 21.43%

GSK EPS Price Prediction Forecast for 2023 - 2025 - 2030

GSK's EPS has decreased In the last two years, from £1.55 to £1.42 – a 8.39% drop. In the next year, analysts believe that EPS will reach £1.47 – an increase of 3.71%. For the next nine years, the forecast is for EPS to grow by 3.58%.

2022 EPS Forecast
£1.47
2023 EPS Forecast
£1.50
2024 EPS Forecast
£1.48
2025 EPS Forecast
£1.46
2026 EPS Forecast
£1.47
2027 EPS Forecast
£1.48
2028 EPS Forecast
£1.48
2029 EPS Forecast
£1.47
2030 EPS Forecast
£1.47
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HOLX Stock Forecast Hologic Inc Outperform 8
$84.68 Buy/Sell $79.86 -2.57%
4523 Stock Forecast Eisai Hold 18
¥8.15k Buy/Sell ¥0.00 -18.99%
CHD Stock Forecast Church & Dwight Co Inc Hold 11
$82.90 Buy/Sell $82.17 2.53%